重组人尿激酶原与经皮冠脉介入术优化急性ST段抬高型心肌梗死预后效果的观察

Observation on the effect of recombinant human prourokinase and percutaneous coronary intervention on optimizing the prognosis of acute ST-segment elevation myocardial infarction

目的:对重组人尿激酶原(rhuPA)和经皮冠脉介入术优化急性ST段抬高型心肌梗死预后效果进行分析。方法:选定2022年6月至2023年7月在本院进行治疗的80例急性ST段抬高型心肌梗死患者作研究对象,随机分成观察组与对照组,均40例。对照组实施经皮冠脉介入术,观察组实施rhuPA+经皮冠脉介入术,将两组治疗结果(心功能、血流分级和不良情况)进行对比。结果:刚入院时,两组心功能指标[左室射血分数(LVEF)、左心室舒张末期内径(LVEDD)、血清肌酸激酶同工酶(CK-MB)、氨基末端B型利钠肽前体(NT-proBNP)]相比较无显著差异,P>0.05;治疗后,观察组LVEF和LVEDD略高于对照组,但差异不具有统计学意义,P>0.05,CK-MB和NT-proBNP比对照组低,P<0.05。观察组的TIMI血流分级和对照组相比,差异不具有统计学意义,P>0.05。观察组不良情况概率低于对照组,P<0.05。结论:针对急性ST段抬高型心肌梗死患者,采用rhuPA+经皮冠脉介入术治疗后其心功能得到明显改善,不良情况概率低,有助于其预后良好。

Objective:To analyze the effect of recombinant human prourokinase(rhuPA)and percutaneous coronary intervention on optimizing the prognosis of acute ST-segment elevation myocardial infarction.Methods:80 patients with acute ST-segment elevation myocardial infarction who were treated in our hospital from June 2022 to July 2023 were randomLy divided into observation group and control group,with 40 cases in each group.The control group was treated with percutaneous coronary intervention,and the observation group was treated with rhuPA+percutaneous coronary intervention.The treatment results(cardiac function,blood flow classification and adverse conditions)of the two groups were compared.Results:At the time of admission,there was no significant difference in cardiac function indexes[left ventricular ejection fraction(LVEF)、left ventricular end-diastolic diameter(LVEDD)、serum creatine kinase isoenzyme(CK-MB)、amino-terminal B-type natriuretic peptide precursor(NT-proBNP)]between the two groups,P>0.05;after treatment,LVEF and LVEDD in the observation group were slightly higher than those in the control group,but the difference was not statistically significant,P>0.05,CK-MB and NT-proBNP were lower than those in the control group,P<0.05.The TIMI flow grade in the observed group was not statistically significant compared with the control group,P>0.05.The probability of adverse events in the observation group was lower than that in the control group,P<0.05.Conclusion:For patients with acute ST-segment elevation myocardial infarction,the cardiac function is significantly improved after rhuPA+percutaneous coronary intervention,and the probability of adverse events is low,which is helpful for its good prognosis.